Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| NIAID CRMS ID#: 38756 | Other Identifier | DAIT NIAID | |
| UM1AI109565 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Stopped to slow rate of enrollment
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University of Washington | OTHER |
| Implicit Bioscience | INDUSTRY |
| Vanderbilt University Medical Center | OTHER |
| PPD Development, LP |
Not provided
Not provided
Not provided
Not provided
This study aims to address the following objectives:
This is a multicenter, randomized, double-blind, placebo-controlled study of IC14, an antibody to CD14, in reducing the severity of respiratory disease in hospitalized Coronavirus Disease 2019 (COVID-19) patients.
Participants will be randomized to IC14 or matching placebo and followed for 60 days after randomization. The study drug will be administered daily on Days 1-4 by intravenous infusion. All participants will receive standard of care antiviral therapy with remdesivir.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| anti-CD14 + SOC | Experimental | Anti-CD14: Anticipated 150 participants randomized to 4 mg/kg on Day 1, 2 mg/kg on Days 2-4 intravenously. Standard of Care (SOC): All participants will receive remdesivir (antiviral) according to current approved dosing for COVID-19 illness. |
|
| Placebo + SOC | Placebo Comparator | Anticipated 150 participants randomized to Placebo diluent on Days 1-4 intravenously. Standard of Care (SOC): All participants will receive remdesivir (antiviral) according to current approved dosing for COVID-19 illness. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| anti-CD14 | Biological | 4 mg/kg on Day 1, 2 mg/kg on Days 2-4 administered intravenously (IV) |
|
| Measure | Description | Time Frame |
|---|---|---|
| The Time to Clinical Recovery, Defined as the Time From Baseline to the First Day That Subject is in Categories 1, 2, or 3 on the Eight-Point Ordinal Scale Through Day 28. | The Primary Endpoint is time to clinical recovery, defined as the time from baseline to the first day that a subject is in categories 1, 2, or 3 on the Eight-Point Ordinal Scale through Day 28 (range 1 [best] to 8 [worst]). The Eight-Point Ordinal Scale is an assessment of the clinical status on each study day. The Scale is defined as follows:
| Within the 28 day period following baseline |
| Measure | Description | Time Frame |
|---|---|---|
| Days Alive and Free of Any Episodes of Acute Respiratory Failure Through Day 28 | Episodes of acute respiratory failure are defined as by need for the following oxygen delivery resources:
|
Not provided
Inclusion Criteria:
Patients included in the study must meet all the following criteria:
Patient or legally authorized representative able to provide informed consent
Presence of SARS-CoV-2 infection documented by positive RT-PCR testing or history of positive RT-PCR test for SARS-CoV-2 within 7 days of screening
Radiologic findings compatible with diagnosis of SARS-CoV-2 pulmonary infection
Hypoxemia as defined by any of the following:
Negative pregnancy test for women of childbearing potential and, must be willing to use birth control for the duration of the study.
Exclusion Criteria:
An individual fulfilling any of the following criteria should be excluded from enrollment in the study:
Receiving non-invasive positive-pressure ventilation through nasal mask, face mask, or nasal plugs
Receiving invasive mechanical ventilation
Patient, surrogate, or physician not committed to full support
--Exception: a participant will not be excluded if he/she would receive all supportive care other than attempts at resuscitation from cardiac arrest)
Anticipated survival <48 hours
Underlying malignancy, or other condition, with estimated life expectancy of less than two months
Significant pre-existing organ dysfunction prior to randomization
Presence of co-existing infection, including, but not limited to:
Ongoing immunosuppression
Current treatment, or treatment within 30 days or five half-lives (whichever is longer) with etanercept (Enbrel®), infliximab (Remicade®), adalimumab (Humira®), certolizumab (Cimzia®), golimumab (Simponi®), anakinra (Kineret®), rilonacept (Arcalyst®), tocilizumab (Actemra®), sarilumab (Kevzara®), siltuximab (Sylvant®), or other potent immunosuppressant or immunomodulatory drugs or treatments
Current treatment with an anti-viral medication for COVID-19 (e.g. hydroxychloroquine, lopinavir/ritonavir), other than remdesivir
Current enrollment in an interventional trial for COVID-19
History of hypersensitivity or idiosyncratic reaction to IC14
Women who are currently breastfeeding
Received a live-attenuated vaccine within 30 days prior to enrollment
Received five or more doses of remdesivir, including the loading dose, outside of the study as treatment for COVID-19, or
Any condition that in the opinion of the treating physician will increase the risk for the participant.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Mark M. Wurfel, MD, PhD | University of Washington: Division of Pulmonary, Critical Care and Sleep Medicine | Study Chair |
| Thomas R. Martin, MD | University of Washington: Division of Pulmonary, Critical Care and Sleep Medicine | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Sarasota Memorial Health Care System | Sarasota | Florida | 34236 | United States | ||
| Virginia Mason Medical Center |
Not provided
| Label | URL |
|---|---|
| National Institutes of Health News Release Describing Study | View source |
| National Institute of Allergy and Infectious Diseases (NIAID) | View source |
| NIAID Division of Allergy, Immunology, and Transplantation (DAIT) |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
8 enrolled participants were not randomized because they did not meet eligibility criteria.
49 participants were enrolled across 5 US sites from April 2021 to January 2022. Of these enrolled, 41 participants were randomized and 40 initiated study treatment. 8 enrolled participants were not randomized because they did not meet eligibility criteria, and one randomized participant did not initiate study treatment because they withdrew their consent.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | IC14 | Subjects received IC14 4 mg/kg intravenously on Day 1, followed by IC14 2 mg/kg/day intravenously on Days 2-4 (totaling 4 consecutive days). Subjects also received remdesivir 200 mg intravenously on Day 1, followed by 100 mg intravenously daily on Days 2-5 (totaling 5 consecutive days). |
| FG001 | Placebo | Subjects received 0.9% w/v Sodium Chloride in a matching bag and volume administered intravenously daily on Days 1-4 (totaling 4 consecutive days). Subjects also received remdesivir 200 mg intravenously on Day 1, followed by 100 mg intravenously daily on Days 2-5 (totaling 5 consecutive days). |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Modified Intent to Treat population (mITT), that included all participants who were randomized and treated with at least one dose of investigational product. Measures reflect the assessment of clinical status at baseline.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | IC14 | Subjects received IC14 4 mg/kg intravenously on Day 1, followed by IC14 2 mg/kg/day intravenously on Days 2-4 (totaling 4 consecutive days). Subjects also received remdesivir 200 mg intravenously on Day 1, followed by 100 mg intravenously daily on Days 2-5 (totaling 5 consecutive days). |
| BG001 |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | The Time to Clinical Recovery, Defined as the Time From Baseline to the First Day That Subject is in Categories 1, 2, or 3 on the Eight-Point Ordinal Scale Through Day 28. | The Primary Endpoint is time to clinical recovery, defined as the time from baseline to the first day that a subject is in categories 1, 2, or 3 on the Eight-Point Ordinal Scale through Day 28 (range 1 [best] to 8 [worst]). The Eight-Point Ordinal Scale is an assessment of the clinical status on each study day. The Scale is defined as follows:
| Modified Intent to Treat population (mITT), that included all participants who were randomized and treated with at least one dose of investigational product. | Posted | Median | 95% Confidence Interval | days | Within the 28 day period following baseline |
Day 0 - Day 60
Adverse Events were collected through Day 60
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | IC14 | Subjects received IC14 4 mg/kg intravenously on Day 1, followed by IC14 2 mg/kg/day intravenously on Days 2-4 (totaling 4 consecutive days). Subjects also received remdesivir 200 mg intravenously on Day 1, followed by 100 mg intravenously daily on Days 2-5 (totaling 5 consecutive days). |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Anemia | Blood and lymphatic system disorders | Systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Leukocytosis | Blood and lymphatic system disorders | Systematic Assessment |
The trial was terminated early because of slow recruitment and cannot be considered fully powered.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Director, Clinical Research Operations Program | DAIT/NIAID | 301-594-7669 | DAITClinicalTrialsGov@niaid.nih.gov |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Feb 22, 2021 | May 16, 2023 | Prot_SAP_001.pdf |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| C000606551 | remdesivir |
Not provided
Not provided
Not provided
| INDUSTRY |
Randomized, Double-Blind, Placebo-Controlled
Not provided
Not provided
Placebo consists of identical-appearing diluent
| Placebo | Other | Placebo administered intravenously on Days 1-4 |
|
|
| remdesivir | Drug | Remdesivir administered intravenously for 5 days beginning with a 200 mg loading dose on Day 1, followed by 100 mg/day on Days 2-5. |
|
|
| Within the 28 day period following baseline. |
| Change in the Ordinal Scale From Baseline to Day 14 | A larger negative change indicates a greater improvement in clinical status from baseline. The Eight-Point Ordinal Scale is an assessment of the clinical status on each study day (1 is best, 8 is worst). The Scale is defined as follows:
| Within the 14 day period following baseline. |
| Change in Ordinal Scale From Baseline to Day 28. | A larger negative change indicates a greater improvement in clinical status from baseline. The Eight-Point Ordinal Scale is an assessment of the clinical status on each study day (1 is best, 8 is worst). The Scale is defined as follows:
| Within the 28 day period following baseline. |
| Ordinal Scale Value on Day 14. | The Eight-Point Ordinal Scale is an assessment of the clinical status on each study day (1 is best, 8 is worst). The Scale is defined as follows:
| Day 14 following baseline. |
| All-Cause Mortality Through Day 28. | Mortality due to all causes during the observation period. | Within the 28 day period following baseline. |
| All-Cause Mortality Through Day 60. | Mortality due to all causes during the observation period. | Within the 60 day period following baseline. |
| Percentage of Participants Alive and Free of Any Episode of Acute Respiratory Failure Through Day 28 | Episodes of acute respiratory failure are defined as by need for the following oxygen delivery resources:
| Within the 28 day period following baseline. |
| Days Alive and Free of Invasive Mechanical Ventilation Through Day 28 | Endotracheal intubation and mechanical ventilation. | Within the 28 day period following baseline. |
| Percentage of Participants Alive and Free of Invasive Mechanical Ventilation Through Day 28 | Endotracheal intubation and mechanical ventilation. | Within the 28 day period following baseline. |
| Percentage of Participants Alive and Discharged From the Hospital Through Day 28 | Participants must be alive and discharged from hospital. | Within the 28 day period following baseline. |
| Percent of Participants Who Begin Corticosteroid Therapy for Worsening COVID-19 Illness After Randomization | Initiation of corticosteroid therapy. | Within the 28 day period following baseline. |
| Serious Adverse Events (SAEs) | Number of serious adverse events | Within the 28 day period following baseline. |
| Adverse Events (AEs) | Number of Grade 3 and 4 clinical and/or laboratory adverse events | Within the 28 day period following baseline. |
| Seattle |
| Washington |
| 98101 |
| United States |
| Harborview Medical Center | Seattle | Washington | 98104 | United States |
| Swedish Medical Center | Seattle | Washington | 98122 | United States |
| University of Washington Medical Center-Montlake | Seattle | Washington | 98195 | United States |
| Centers for Disease Control and Prevention -COVID-19 resources | View source |
| Withdrawal by Subject |
|
| Placebo |
Subjects received 0.9% w/v Sodium Chloride in a matching bag and volume administered intravenously daily on Days 1-4 (totaling 4 consecutive days). Subjects also received remdesivir 200 mg intravenously on Day 1, followed by 100 mg intravenously daily on Days 2-5 (totaling 5 consecutive days). |
| BG002 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race/Ethnicity, Customized | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| Assessment of Clinical Status According to Eight-Point Ordinal Scale | The Eight-Point Ordinal Scale - assessment of the clinical status at baseline:
| Count of Participants | Participants |
|
| ID | Title | Description |
|---|---|---|
| OG000 | IC14 | Subjects received IC14 4 mg/kg intravenously on Day 1, followed by IC14 2 mg/kg/day intravenously on Days 2-4 (totaling 4 consecutive days). Subjects also received remdesivir 200 mg intravenously on Day 1, followed by 100 mg intravenously daily on Days 2-5 (totaling 5 consecutive days). |
| OG001 | Placebo | Subjects received 0.9% w/v Sodium Chloride in a matching bag and volume administered intravenously daily on Days 1-4 (totaling 4 consecutive days). Subjects also received remdesivir 200 mg intravenously on Day 1, followed by 100 mg intravenously daily on Days 2-5 (totaling 5 consecutive days). |
|
|
|
| Secondary | Days Alive and Free of Any Episodes of Acute Respiratory Failure Through Day 28 | Episodes of acute respiratory failure are defined as by need for the following oxygen delivery resources:
| Modified Intent to Treat population (mITT), that included all participants who were randomized and treated with at least one dose of investigational product. | Posted | Count of Participants | Participants | Within the 28 day period following baseline. |
|
|
|
|
| Secondary | Change in the Ordinal Scale From Baseline to Day 14 | A larger negative change indicates a greater improvement in clinical status from baseline. The Eight-Point Ordinal Scale is an assessment of the clinical status on each study day (1 is best, 8 is worst). The Scale is defined as follows:
| Modified Intent to Treat population (mITT), that included all participants who were randomized and treated with at least one dose of investigational product, who additionally had data collected on Day 14. | Posted | Mean | Standard Deviation | units on a scale | Within the 14 day period following baseline. |
|
|
|
|
| Secondary | Change in Ordinal Scale From Baseline to Day 28. | A larger negative change indicates a greater improvement in clinical status from baseline. The Eight-Point Ordinal Scale is an assessment of the clinical status on each study day (1 is best, 8 is worst). The Scale is defined as follows:
| Modified Intent to Treat population (mITT), that included all participants who were randomized and treated with at least one dose of investigational product, who additionally had data collected on Day 28. | Posted | Mean | Standard Deviation | units on a scale | Within the 28 day period following baseline. |
|
|
|
|
| Secondary | Ordinal Scale Value on Day 14. | The Eight-Point Ordinal Scale is an assessment of the clinical status on each study day (1 is best, 8 is worst). The Scale is defined as follows:
| Modified Intent to Treat population (mITT), that included all participants who were randomized and treated with at least one dose of investigational product, who additionally had data collected on Day 14. | Posted | Mean | Standard Deviation | units on a scale | Day 14 following baseline. |
|
|
|
|
| Secondary | All-Cause Mortality Through Day 28. | Mortality due to all causes during the observation period. | Modified Intent to Treat population (mITT), that included all participants who were randomized and treated with at least one dose of investigational product. | Posted | Count of Participants | Participants | Within the 28 day period following baseline. |
|
|
|
|
| Secondary | All-Cause Mortality Through Day 60. | Mortality due to all causes during the observation period. | Modified Intent to Treat population (mITT), that included all participants who were randomized and treated with at least one dose of investigational product. | Posted | Count of Participants | Participants | Within the 60 day period following baseline. |
|
|
|
|
| Secondary | Percentage of Participants Alive and Free of Any Episode of Acute Respiratory Failure Through Day 28 | Episodes of acute respiratory failure are defined as by need for the following oxygen delivery resources:
| Modified Intent to Treat population (mITT), that included all participants who were randomized and treated with at least one dose of investigational product. | Posted | Count of Participants | Participants | Within the 28 day period following baseline. |
|
|
|
|
| Secondary | Days Alive and Free of Invasive Mechanical Ventilation Through Day 28 | Endotracheal intubation and mechanical ventilation. | Modified Intent to Treat population (mITT), that included all participants who were randomized and treated with at least one dose of investigational product. | Posted | Count of Participants | Participants | Within the 28 day period following baseline. |
|
|
|
|
| Secondary | Percentage of Participants Alive and Free of Invasive Mechanical Ventilation Through Day 28 | Endotracheal intubation and mechanical ventilation. | Modified Intent to Treat population (mITT), that included all participants who were randomized and treated with at least one dose of investigational product. | Posted | Count of Participants | Participants | Within the 28 day period following baseline. |
|
|
|
|
| Secondary | Percentage of Participants Alive and Discharged From the Hospital Through Day 28 | Participants must be alive and discharged from hospital. | Modified Intent to Treat population (mITT), that included all participants who were randomized and treated with at least one dose of investigational product. | Posted | Count of Participants | Participants | Within the 28 day period following baseline. |
|
|
|
|
| Secondary | Percent of Participants Who Begin Corticosteroid Therapy for Worsening COVID-19 Illness After Randomization | Initiation of corticosteroid therapy. | Modified Intent to Treat population (mITT), that included all participants who were randomized and treated with at least one dose of investigational product. | Posted | Count of Participants | Participants | Within the 28 day period following baseline. |
|
|
|
|
| Secondary | Serious Adverse Events (SAEs) | Number of serious adverse events | All participants who initiated study treatment. | Posted | Number | Serious Adverse Events | Within the 28 day period following baseline. |
|
|
|
| Secondary | Adverse Events (AEs) | Number of Grade 3 and 4 clinical and/or laboratory adverse events | All participants who initiated study treatment. | Posted | Number | Adverse Events | Within the 28 day period following baseline. |
|
|
|
| 1 |
| 20 |
| 4 |
| 20 |
| 16 |
| 20 |
| EG001 | Placebo | Subjects received 0.9% w/v Sodium Chloride in a matching bag and volume administered intravenously daily on Days 1-4 (totaling 4 consecutive days). Subjects also received remdesivir 200 mg intravenously on Day 1, followed by 100 mg intravenously daily on Days 2-5 (totaling 5 consecutive days). | 1 | 20 | 1 | 20 | 13 | 20 |
| Atrial fibrillation | Cardiac disorders | Systematic Assessment |
|
| Acute pancreatitis | Gastrointestinal disorders | Systematic Assessment |
|
| Gastric ulcer | Gastrointestinal disorders | Systematic Assessment |
|
| Lung infection | Infections and infestations | Systematic Assessment |
|
| Acute renal failure | Renal and urinary disorders | Systematic Assessment |
|
| Hypoxemia | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Respiratory failure | Renal and urinary disorders | Systematic Assessment |
|
| Thromboembolic event | Vascular disorders | Systematic Assessment |
|
| Myocardial infarction | Cardiac disorders | Systematic Assessment |
|
| Tachycardia | Cardiac disorders | Systematic Assessment |
|
| Ventricular tachycardia | Cardiac disorders | Systematic Assessment |
|
| Blurred vision | Eye disorders | Systematic Assessment |
|
| Detachment of retinal pigment epithelium | Eye disorders | Systematic Assessment |
|
| Dry eye syndrome | Eye disorders | Systematic Assessment |
|
| Dry eyes | Eye disorders | Systematic Assessment |
|
| Dry macular degeneration | Eye disorders | Systematic Assessment |
|
| Eye pain | Eye disorders | Systematic Assessment |
|
| Glaucoma | Eye disorders | Systematic Assessment |
|
| Incipient senile cataract | Eye disorders | Systematic Assessment |
|
| Lattice degeneration of retina | Eye disorders | Systematic Assessment |
|
| Meibomian gland dysfunction | Eye disorders | Systematic Assessment |
|
| Neovascular age-related macular degeneration | Eye disorders | Systematic Assessment |
|
| Retinal hemorrhage | Eye disorders | Systematic Assessment |
|
| Retinal macroaneurysm | Eye disorders | Systematic Assessment |
|
| Retinal tear | Eye disorders | Systematic Assessment |
|
| Senile nuclear sclerosis | Eye disorders | Systematic Assessment |
|
| Abdominal pain | Gastrointestinal disorders | Systematic Assessment |
|
| Epstein-Barr virus infection | Infections and infestations | Systematic Assessment |
|
| Perianal abscess | Gastrointestinal disorders | Systematic Assessment |
|
| Thrush | Gastrointestinal disorders | Systematic Assessment |
|
| Conjunctival abrasion | Injury, poisoning and procedural complications | Systematic Assessment |
|
| Alanine aminotransferase increased | Investigations | Systematic Assessment |
|
| Aspartate aminotransferase increased | Investigations | Systematic Assessment |
|
| Cardiac troponin increased | Investigations | Systematic Assessment |
|
| Creatinine increased | Investigations | Systematic Assessment |
|
| GGT increased | Investigations | Systematic Assessment |
|
| Sputum abnormal | Investigations | Systematic Assessment |
|
| Hyperglycemia | Metabolism and nutrition disorders | Systematic Assessment |
|
| Hyperkalemia | Metabolism and nutrition disorders | Systematic Assessment |
|
| Hypokalemia | Metabolism and nutrition disorders | Systematic Assessment |
|
| Hyponatremia | Metabolism and nutrition disorders | Systematic Assessment |
|
| Leg pain | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
| Pain in extremity | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
| Pain in thigh | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
| Choroidal nevus | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Systematic Assessment |
|
| Headache tension | Nervous system disorders | Systematic Assessment |
|
| Paresthesia | Nervous system disorders | Systematic Assessment |
|
| Acute psychosis | Psychiatric disorders | Systematic Assessment |
|
| Anxiety | Psychiatric disorders | Systematic Assessment |
|
| Renal stone | Renal and urinary disorders | Systematic Assessment |
|
| Calcified lung nodule | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Hemoptysis | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Hypoxia | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Pulmonary embolism | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Respiratory failure | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Localized maculopapular rash | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
Not provided
Not provided
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| 27 days |
|
| 28 days |
|